首页> 外文期刊>Molecular biology reports >The frequency of factor V Leiden mutation, ACE gene polymorphism, serum ACE activity and response to ACE inhibitor and angiotensin II receptor antagonist drugs in Iranians type II diabetic patients with microalbuminuria
【24h】

The frequency of factor V Leiden mutation, ACE gene polymorphism, serum ACE activity and response to ACE inhibitor and angiotensin II receptor antagonist drugs in Iranians type II diabetic patients with microalbuminuria

机译:伊朗II型糖尿病合并微量白蛋白尿患者的V因子莱顿突变频率,ACE基因多态性,血清ACE活性以及对ACE抑制剂和血管紧张素II受体拮抗剂的反应

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The aim of present study was to determine if factor V Leiden (FVL) mutation and angiotensin converting enzyme insertion/deletion (ACE I/D) polymorphism are associated with diabetic nephropathy (DN) among Kurdish population from Western Iran. This case-control study comprised 144 unrelated adult type 2 diabetic mellitus patients (T2DM) including 72 patients with microalbuminuria and 72 age and sex matched patients without nephropathy. The ACE I/D polymorphism and FVL mutation were detected by polymerase chain reaction (PCR) and PCR-RFLP, respectively. The frequency of FVL G1691A and ACE D allele in T2DM patients with microalbuminuria were 1.6 and 57%, respectively and in normoalbuminuric T2DM patients were 4.9 and 58.3%, respectively (P>0.05). ACE genotypes affected on serum ACE activity and a better response to ACE inhibitor therapy (captopril) compared to angiotensin II receptor antagonist (losartan) was obtained with significant reduction of ACE activity in diabetic patients without nephropathy carrying DD genotype. However, the beneficial effect of losartan therapy was observed in microalbuminuric patients with II genotype compared to ID and DD genotypes.
机译:本研究的目的是确定伊朗西部库尔德人人群中的V因子莱顿(FVL)突变和血管紧张素转化酶插入/缺失(ACE I / D)多态性是否与糖尿病肾病(DN)相关。这项病例对照研究包括144位不相关的成人2型糖尿病患者(T2DM),其中包括72例微量白蛋白尿患者和72例年龄和性别相匹配的无肾病患者。 ACE I / D多态性和FVL突变分别通过聚合酶链反应(PCR)和PCR-RFLP检测。 T2DM伴有微量白蛋白尿的患者FVL G1691A和ACE D等位基因的频率分别为1.6%和57%,而正常白蛋白尿T2DM患者的FVL G1691A和ACE D等位基因的频率分别为4.9%和58.3%(P> 0.05)。与没有血管紧张素II肾病的糖尿病患者相比,获得了与血管紧张素II受体拮抗剂(氯沙坦)相比对血清ACE活性有影响的ACE基因型,并且对ACE抑制剂治疗(卡托普利)的反应更好。但是,与ID和DD基因型相比,氯沙坦治疗在II基因型微蛋白尿患者中观察到了有益效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号